11.02.11
West and Vetter have entered into a collaboration to provide customers with filled Daikyo Crystal Zenith syringes. West has been working with Vetter to help customers transition to the Daikyo Crystal Zenith syringe system. This partnership allows both companies to develop and optimize the manufacturing, validation and packaging of the non-glass syringe system to engineer compatibility with the filling capabilities and requirements at Vetter. Media fills and equipment validation are underway for the 1mL long insert needle syringe system.
Investments at Vetter’s facilities in Germany and the new Chicago development facility have been made to support the collaboration. Initially capabilities will include early-phase clinical filling in Germany. Options for commercial-scale filling will be available.
“We are delighted to have the opportunity to offer our customers an innovative solution, combining the benefits of the Daikyo Crystal Zenith syringe system with the biopharmaceutical fill and finish capabilities of one of the world’s leading CDMOs,” said Donald E. Morel, Jr., Ph.D., West’s chairman and chief executive officer. “Vetter is an established market leader in the manufacture of aseptically prefilled drug-delivery systems for biopharmaceutical products, and we are pleased to have this ongoing relationship.”
Investments at Vetter’s facilities in Germany and the new Chicago development facility have been made to support the collaboration. Initially capabilities will include early-phase clinical filling in Germany. Options for commercial-scale filling will be available.
“We are delighted to have the opportunity to offer our customers an innovative solution, combining the benefits of the Daikyo Crystal Zenith syringe system with the biopharmaceutical fill and finish capabilities of one of the world’s leading CDMOs,” said Donald E. Morel, Jr., Ph.D., West’s chairman and chief executive officer. “Vetter is an established market leader in the manufacture of aseptically prefilled drug-delivery systems for biopharmaceutical products, and we are pleased to have this ongoing relationship.”